Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis

Current Opinion in Lipidology

Volumn 24, Issue 2, 2013, Pages 116-122

  Mäkinen, Petri ^a   Ylä Herttuala, Seppo ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

antisense oligonucleotide; atherosclerosis; dyslipidemia; gene silencing; miRNA; siRNA

Indexed keywords

ANTAGOMIR; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B100; CHOLESTEROL; KEXIN; KEXIN 9; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 126; MICRORNA 155; MIPOMERSEN; MONOCYTE CHEMOTACTIC PROTEIN 1; RNA; SCAVENGER RECEPTOR A; SMALL INTERFERING RNA; SORTILIN; SUBTILISIN; TKM APOB; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; DNA MODIFICATION; DRUG EFFICACY; DYSLIPIDEMIA; EPIGENETICS; GENE SILENCING; GENE TARGETING; GENE THERAPY; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; KNOCKOUT MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; EPIGENESIS, GENETIC; GENETIC THERAPY; HUMANS; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PLAQUE, ATHEROSCLEROTIC; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84875210174     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32835da13c     Document Type: Review

References (70)

1. Yla-Herttuala S. Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. Mol Ther 2012; 20: 1831-1832.
2. Hedman M, Hartikainen J, Yla-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther 2011; 18: 743-749.
3. Muona K, Makinen K, Hedman M, et al. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther 2012; 19: 392-395.
4. Wiesner P, Choi SH, Almazan F, et al. Low doses of lipopolysaccharide and minimally oxidized low-density lipoprotein cooperatively activate macrophages via nuclear factor kappa B and activator protein-1: possible mechanism for acceleration of atherosclerosis by subclinical endotoxemia. Circ Res 2010; 107: 56-65.
5. Rajamaki K, Lappalainen J, Oorni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010; 5: e11765.
6. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-1361.
7. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012; 151: 138-152. The study describes desmosterol as a mediator in lipid homeostasis and inflammation in foam cells.
8. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178.
9. Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25: 1149-1157.
10. Tadin-Strapps M, Peterson LB, Cumiskey AM, et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J Lipid Res 2011; 52: 1084-1097.
11. Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-433.
12. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, et al. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J Clin Invest 1991; 87: 1146-1152.
13. Broisat A, Hernot S, Toczek J, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res 2012; 110: 927-937.
14. Kagaya H, Oba M, Miura Y, et al. Impact of polyplex micelles installed with cyclic RGD peptide as ligand on gene delivery to vascular lesions. Gene Ther 2012; 19: 61-69.
15. Lee GY, Kim JH, Oh GT, et al. Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J Control Release 2011; 155: 211-217.
16. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008; 117: 3206-3215.
17. Tsimikas S, Miyanohara A, Hartvigsen K, et al. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. J Am Coll Cardiol 2011; 58: 1715-1727.
18. Yla-Herttuala S, Bentzon JF, Daemen M, et al. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology [ESC] Working Group on Atherosclerosis and Vascular Biology. Thromb Haemost 2011; 106: 1-19. A thorough description of vulnerable plaque pathogenesis, detection, and stabilization.
19. Yla-Herttuala S, Nikkari T, Hirvonen J, et al. Biochemical composition of coronary arteries in Finnish children. Arteriosclerosis 1986; 6: 230-236.
20. Karvinen H, Pasanen E, Rissanen TT, et al. Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle. Gene Ther 2011; 18: 1166-1172.
21. Makinen PI, Koponen JK, Karkkainen AM, et al. Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. J Gene Med 2006; 8: 433-441.
22. Makinen PI, Lappalainen JP, Heinonen SE, et al. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc Res 2010; 88: 530-538.
23. Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114: 1729-1735.
24. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
25. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33: 1142-1149. Proof of efficiency of mipomersen in phase III study of high-risk cardiovascular patients.
26. Straarup EM, Fisker N, Hedtjarn M, et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and nonhuman primates. Nucleic Acids Res 2010; 38: 7100-7111.
27. Koornneef A, Maczuga P, van Logtenstein R, et al. Apolipoprotein B knockdown by AAV-delivered shRNA lowers plasma cholesterol in mice. Mol Ther 2011; 19: 731-740.
28. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in nonhuman primates. Nature 2006; 441: 111-114.
29. Moschos SA, Frick M, Taylor B, et al. Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA [siRNA] and locked nucleic acid [LNA] antisense. Mol Ther 2011; 19: 2163-2168. This study demonstrates an alternative intratracheal delivery route for antisense oligonucleotides to downregulate gene expression in the liver.
30. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282: 18602-18612.
31. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007; 48: 763-767.
32. Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther 2012; 20: 376-381.
33. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008; 105: 11915-11920.
34. Fitzgerald K, Frank-Kamenetsky M, Mant T, et al. Phase I safety, pharmacokinetic, and pharmacodynamic results for ALN-PCS, a novel RNAi therapeutic for the treatment of hypercholesterolemia. Arterioscler Thromb Vasc Biol 2012; 32: A67. First nucleic acid-based trial targeting PCSK9 in humans. RNAi-based silencing of PCSK9 led to a significant lowering of LDL without signs of toxicity.
35. Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature 2010; 466: 714-719.
36. Strong A, Ding Q, Edmondson AC, et al. Hepatic sortilin regulates both apolipoprotein B secretion and LDL catabolism. J Clin Invest 2012; 122: 2807-2816. A study providing proof for the association between sort1 and LDL levels.
37. Avraham-Davidi I, Ely Y, Pham VN, et al. ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1. Nat Med 2012; 18: 967-973. This study identifies ApoB-containing lipoproteins as direct modulators of endothelial cells and angiogenesis by a novel mechanism through VEGF receptor 1.
38. Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002; 277: 49982-49988.
39. Jalkanen J, Leppanen P, NarvanenO, et al. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice. Atherosclerosis 2003; 169: 95-103.
40. Jalkanen J, Leppanen P, Pajusola K, et al. Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Mol Ther 2003; 8: 903-910.
41. Kzhyshkowska J, Neyen C, Gordon S. Role of macrophage scavenger receptors in atherosclerosis. Immunobiology 2012; 217: 492-502.
42. KivelaAM, Makinen PI, Jyrkkanen HK, et al. Sulforaphane inhibits endothelial lipase expression through NF-kappaB in endothelial cells. Atherosclerosis 2010; 213: 122-128.
43. Liu XL, Zhang PF, Ding SF, et al. Local gene silencing of monocyte chemoattractant protein-1 prevents vulnerable plaque disruption in apolipoprotein E-knockout mice. PLoS One 2012; 7: e33497.
44. Leuschner F, Dutta P, Gorbatov R, et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011; 29: 1005-1010.
45. Raitoharju E, Lyytikainen LP, Levula M, et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis 2011; 219: 211-217.
46. Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570-1573.
47. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566-1569.
48. Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478: 404-407. A proof of concept that function of miRNA can be blocked by anti-miRNAs in primates affecting plasma cholesterol levels.
49. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12: 735-739.
50. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
51. Elmen J, Lindow M, Schutz S, et al. LNA-mediated microRNA silencing in nonhuman primates. Nature 2008; 452: 896-899.
52. Ramirez CM, Davalos A, Goedeke L, et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler Thromb Vasc Biol 2011; 31: 2707-2714.
53. Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2012. [Epub ahead of print]. doi: 10.1002/hep.25846
54. Harris TA, Yamakuchi M, Ferlito M, et al. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci U S A 2008; 105: 1516-1521.
55. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15: 261-271.
56. Nicoli S, Standley C, Walker P, et al. MicroRNA-mediated integration of haemodynamics and VEGF signalling during angiogenesis. Nature 2010; 464: 1196-1200.
57. Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells-feedback control of inflammation. J Immunol 2010; 184: 21-25.
58. Pulkkinen KH, Yla-Herttuala S, Levonen AL. Heme oxygenase 1 is induced by miR-155 via reduced BACH1 translation in endothelial cells. Free Radic Biol Med 2011; 51: 2124-2131.
59. Donners MM, Wolfs IM, Stoger LJ, et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 2012; 7: e35877.
60. Nazari-Jahantigh M, Wei Y, Noels H, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012; 122: 4190-4202.
61. Cordes KR, Sheehy NT, White MP, et al. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009; 460: 705-710.
62. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009; 119: 2634-2647.
63. Hergenreider E, Heydt S, Treguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012; 14: 249-256. Description of crosstalk between endothelial cells and vascular SMCs through miRNA-143/145-related signaling.
64. Lovren F, Pan Y, Quan A, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012; 126: S81-90.
65. Torella D, Iaconetti C, Catalucci D, et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res 2011; 109: 880-893.
66. Wang YS, Wang HY, Liao YC, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res 2012; 95: 517-526.
67. Turunen MP, Lehtola T, Heinonen SE, et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ Res 2009; 105: 604-609.
68. Findeisen HM, Gizard F, Zhao Y, et al. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol 2011; 31: 851-860.
69. Hiltunen MO, Turunen MP, Hakkinen TP, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med 2002; 7: 5-11.
70. Sharma P, Kumar J, Garg G, et al. Detection of altered global DNA methylation in coronary artery disease patients. DNA Cell Biol 2008; 27: 357-365.